Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

July 16, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces progress on initiation of a Phase 2a study of tolimidone in Type 1 diabetes ("T1D"). Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "We are excited to initiate our clinical program in Type 1 diabetes with the University of Alberta and build on the extensive tolim ...